This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignees: Centre Hospitalier Unviersitaire De Caen, Katholieke Universiteit Leuven, National Institute of Health and Medical Research. Active years: 2019.
Company Filing History:


Years Active: 2019
Title: Marina Rubio: Innovator in Thrombotic Disorder Treatments
Introduction
Marina Rubio is a prominent inventor based in Caen, France. She has made significant contributions to the field of medical science, particularly in the treatment of thrombotic disorders. Her innovative work has led to the development of a unique bispecific inhibitor that targets specific proteins involved in thrombotic conditions.
Latest Patents
Marina Rubio holds a patent for her invention titled "Dual targeting of TAFI and PAI-1." This patent discloses a bispecific inhibitor designed for use in treating thrombotic disorders, including acute conditions such as stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies that target TAFI and PAI-1, demonstrating efficacy both in the presence and absence of plasminogen activators like tissue-type plasminogen activator (tPA). She has 1 patent to her name.
Career Highlights
Throughout her career, Marina has worked with esteemed institutions, including Katholieke Universiteit Leuven and Université De Caen Basse Normandie. Her research has focused on advancing therapeutic options for patients suffering from thrombotic disorders, showcasing her dedication to improving healthcare outcomes.
Collaborations
Marina has collaborated with notable professionals in her field, including Nick Geukens and Ann Gils. These partnerships have contributed to her innovative research and the successful development of her patented technologies.
Conclusion
Marina Rubio is a trailblazer in the medical field, particularly in the treatment of thrombotic disorders. Her innovative patent and collaborations highlight her commitment to advancing medical science and improving patient care.